MorphoSys AG (SIX: MOR.SW) Stock Competitors & Peer Comparison
See MOR.SW's competitors and their performance on the SIX and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MOR.SW and its SIX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MOR.SW | CHF 102.00 | +0.00% | 2.4B | -4.03 | -CHF 25.33 | N/A |
| LONN.SW | CHF 631.80 | +0.57% | 44.1B | 39.66 | CHF 15.93 | +0.79% |
| BANB.SW | CHF 82.85 | +0.36% | 6.2B | 41.68 | CHF 1.99 | +1.09% |
| IDIA.SW | CHF 4.19 | -1.09% | 1.1B | -4.84 | -CHF 0.87 | N/A |
| BSLN.SW | CHF 68.50 | -1.15% | 848.8M | 16.13 | CHF 4.25 | N/A |
| SANN.SW | CHF 13.84 | -1.98% | 211.8M | -6.07 | -CHF 2.28 | N/A |
| NWRN.SW | CHF 8.64 | -0.46% | 176.7M | -6.41 | -CHF 1.35 | N/A |
| MOLN.SW | CHF 3.14 | +3.63% | 120.3M | -2.31 | -CHF 1.36 | N/A |
| RLF.SW | CHF 2.89 | +0.87% | 36.3M | -2.12 | -CHF 1.36 | N/A |
| MMTX.SW | CHF 0.16 | +5.12% | 27.2M | -0.67 | -CHF 0.24 | N/A |
Stock Comparison
Lonza Group AG (SIX: LONN.SW)
MOR.SW vs LONN.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, LONN.SW has a market cap of 44.1B. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while LONN.SW trades at CHF 631.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas LONN.SW's P/E ratio is 39.66. In terms of profitability, MOR.SW's ROE is -1.84%, compared to LONN.SW's ROE of -0.01%. Regarding short-term risk, MOR.SW is not fully comparable compared to LONN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check LONN.SW's competition here
Bachem Holding AG (SIX: BANB.SW)
MOR.SW vs BANB.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, BANB.SW has a market cap of 6.2B. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while BANB.SW trades at CHF 82.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas BANB.SW's P/E ratio is 41.68. In terms of profitability, MOR.SW's ROE is -1.84%, compared to BANB.SW's ROE of +0.10%. Regarding short-term risk, MOR.SW is not fully comparable compared to BANB.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check BANB.SW's competition here
Idorsia Ltd (SIX: IDIA.SW)
MOR.SW vs IDIA.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, IDIA.SW has a market cap of 1.1B. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while IDIA.SW trades at CHF 4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas IDIA.SW's P/E ratio is -4.84. In terms of profitability, MOR.SW's ROE is -1.84%, compared to IDIA.SW's ROE of +0.27%. Regarding short-term risk, MOR.SW is not fully comparable compared to IDIA.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check IDIA.SW's competition here
Basilea Pharmaceutica AG (SIX: BSLN.SW)
MOR.SW vs BSLN.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, BSLN.SW has a market cap of 848.8M. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while BSLN.SW trades at CHF 68.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas BSLN.SW's P/E ratio is 16.13. In terms of profitability, MOR.SW's ROE is -1.84%, compared to BSLN.SW's ROE of +0.36%. Regarding short-term risk, MOR.SW is not fully comparable compared to BSLN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check BSLN.SW's competition here
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW)
MOR.SW vs SANN.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, SANN.SW has a market cap of 211.8M. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while SANN.SW trades at CHF 13.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas SANN.SW's P/E ratio is -6.07. In terms of profitability, MOR.SW's ROE is -1.84%, compared to SANN.SW's ROE of +3.55%. Regarding short-term risk, MOR.SW is not fully comparable compared to SANN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check SANN.SW's competition here
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW)
MOR.SW vs NWRN.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, NWRN.SW has a market cap of 176.7M. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while NWRN.SW trades at CHF 8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas NWRN.SW's P/E ratio is -6.41. In terms of profitability, MOR.SW's ROE is -1.84%, compared to NWRN.SW's ROE of +2.58%. Regarding short-term risk, MOR.SW is not fully comparable compared to NWRN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check NWRN.SW's competition here
Molecular Partners AG (SIX: MOLN.SW)
MOR.SW vs MOLN.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, MOLN.SW has a market cap of 120.3M. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while MOLN.SW trades at CHF 3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas MOLN.SW's P/E ratio is -2.31. In terms of profitability, MOR.SW's ROE is -1.84%, compared to MOLN.SW's ROE of -0.68%. Regarding short-term risk, MOR.SW is not fully comparable compared to MOLN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check MOLN.SW's competition here
Relief Therapeutics Holding AG (SIX: RLF.SW)
MOR.SW vs RLF.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, RLF.SW has a market cap of 36.3M. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while RLF.SW trades at CHF 2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas RLF.SW's P/E ratio is -2.12. In terms of profitability, MOR.SW's ROE is -1.84%, compared to RLF.SW's ROE of -0.39%. Regarding short-term risk, MOR.SW is not fully comparable compared to RLF.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check RLF.SW's competition here
MindMaze Therapeutics Holding S.A. (SIX: MMTX.SW)
MOR.SW vs MMTX.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, MMTX.SW has a market cap of 27.2M. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while MMTX.SW trades at CHF 0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas MMTX.SW's P/E ratio is -0.67. In terms of profitability, MOR.SW's ROE is -1.84%, compared to MMTX.SW's ROE of N/A. Regarding short-term risk, MOR.SW is not fully comparable compared to MMTX.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check MMTX.SW's competition here
Spexis AG (SIX: SPEX.SW)
MOR.SW vs SPEX.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, SPEX.SW has a market cap of 3.9M. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while SPEX.SW trades at CHF 0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas SPEX.SW's P/E ratio is -0.15. In terms of profitability, MOR.SW's ROE is -1.84%, compared to SPEX.SW's ROE of N/A. Regarding short-term risk, MOR.SW is not fully comparable compared to SPEX.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check SPEX.SW's competition here
Addex Therapeutics Ltd (SIX: ADXN.SW)
MOR.SW vs ADXN.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, ADXN.SW has a market cap of 2.8M. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while ADXN.SW trades at CHF 0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas ADXN.SW's P/E ratio is -0.40. In terms of profitability, MOR.SW's ROE is -1.84%, compared to ADXN.SW's ROE of -1.73%. Regarding short-term risk, MOR.SW is not fully comparable compared to ADXN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check ADXN.SW's competition here
ObsEva S.A. (SIX: OBSN.SW)
MOR.SW vs OBSN.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, OBSN.SW has a market cap of 140.6K. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while OBSN.SW trades at CHF 0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas OBSN.SW's P/E ratio is -0.00. In terms of profitability, MOR.SW's ROE is -1.84%, compared to OBSN.SW's ROE of -1.46%. Regarding short-term risk, MOR.SW is not fully comparable compared to OBSN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check OBSN.SW's competition here
Cassiopea S.p.A. (SIX: SKIN.SW)
MOR.SW vs SKIN.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, SKIN.SW has a market cap of 0. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while SKIN.SW trades at CHF 35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas SKIN.SW's P/E ratio is -28.13. In terms of profitability, MOR.SW's ROE is -1.84%, compared to SKIN.SW's ROE of -1.27%. Regarding short-term risk, MOR.SW is not fully comparable compared to SKIN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check SKIN.SW's competition here
Polyphor AG (SIX: POLN.SW)
MOR.SW vs POLN.SW Comparison October 2026
MorphoSys AG (SIX: MOR.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MOR.SW stands at 2.4B. In comparison, POLN.SW has a market cap of 0. Regarding current trading prices, MOR.SW is priced at CHF 102.00 on the SIX, while POLN.SW trades at CHF 1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MOR.SW currently has a P/E ratio of -4.03, whereas POLN.SW's P/E ratio is -0.46. In terms of profitability, MOR.SW's ROE is -1.84%, compared to POLN.SW's ROE of -1.32%. Regarding short-term risk, MOR.SW is not fully comparable compared to POLN.SW. This indicates unavailable risk data in terms of short-term price fluctuations for MOR.SW.Check POLN.SW's competition here